Target intelligence / Profile preview

Cullin-RING ligase 4-Cereblon E3 ubiquitin ligase complex (CRL4-CRBN)

Target
CRL4-CRBN
Molecular classification
Enzyme, E3 ubiquitin ligase, Multiprotein complex
01

Overview

The Cullin-RING ligase 4-Cereblon (CRL4-CRBN) E3 ubiquitin ligase complex is a multi-protein assembly that plays a critical role in targeted protein degradation via the ubiquitin-proteasome system. The complex is composed of the scaffold protein Cullin-4 (CUL4A or CUL4B), Ring-Box 1 (RBX1/ROC1), DNA damage-binding protein 1 (DDB1), and the substrate recognition receptor Cereblon (CRBN). Under physiological conditions, the complex regulates cellular homeostasis, cell cycle progression, and embryonic development by tagging specific native substrates with ubiquitin for proteasomal degradation.

The CRL4-CRBN complex is a highly validated therapeutic target, particularly in hematological malignancies such as multiple myeloma and myelodysplastic syndromes. Immunomodulatory imide drugs (IMiDs) like thalidomide, lenalidomide, and pomalidomide, as well as next-generation cereblon E3 ligase modulators (CELMoDs), bind directly to the tri-tryptophan pocket of CRBN. This binding alters the substrate specificity of the complex, redirecting it to recruit and degrade non-physiological 'neosubstrates' such as the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are essential for myeloma cell survival. Furthermore, the CRL4-CRBN complex is widely exploited in targeted protein degradation (TPD) drug discovery, where proteolysis-targeting chimeras (PROTACs) hijack the complex to selectively degrade typically undruggable disease-causing proteins.

Other names
CRL4-CRBN complexCRL4(CRBN) E3 ubiquitin ligase complexCUL4-DDB1-RBX1-CRBN complexCullin-RING ligase 4-Cereblon complexCullin 4-RING E3 ubiquitin ligase complex
02

Mechanism of action

Small-molecule modulators (IMiDs and CELMoDs) bind to the cereblon (CRBN) subunit of the CRL4-CRBN complex, altering its surface topography and substrate specificity to recruit and ubiquitinate non-native 'neosubstrate' proteins (e.g., IKZF1, IKZF3, SALL4, GSPT1) for proteasomal degradation. Additionally, proteolysis-targeting chimeras (PROTACs) utilize the complex to induce proximity-driven ubiquitination and degradation of specific proteins of interest.

03

Biological functions

Protein ubiquitinationProtein degradationCell cycle regulationDNA damage responseSignal transductionTranscriptional regulationEmbryonic development
04

Disease associations

CancerMultiple myelomaMyelodysplastic syndromeB-cell lymphomaInflammatory diseaseAutoimmune disease
05

Safety considerations

Teratogenicity (e.g., phocomelia, limb malformations mediated by SALL4 degradation)Myelosuppression (neutropenia, thrombocytopenia, anemia mediated by IKZF1/IKZF3 degradation)Peripheral neuropathyVenous thromboembolism (VTE)Secondary primary malignanciesDrug resistance due to CRBN mutations or downregulation
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

Cereblon (CRBN) expression levelCullin-4A (CUL4A) expression levelDNA damage-binding protein 1 (DDB1) expression levelIKZF1 (Ikaros) degradationIKZF3 (Aiolos) degradationCSNK1A1 (Casein kinase 1A1) degradationGSPT1 degradation

Beyond the preview

Go deeper on Cullin-RING ligase 4-Cereblon E3 ubiquitin ligase complex (CRL4-CRBN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cullin-RING ligase 4-Cereblon E3 ubiquitin ligase complex (CRL4-CRBN).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call